The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Jubilant Pharmova has posted net profit of Rs. 839.4 crores for the Financial Year ended March 31, 2025
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
The USFDA has issued 5 observations pursuant to the completion of audit
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
FDA has concluded that this inspection is 'closed'
Subscribe To Our Newsletter & Stay Updated
